Area of research
Molecular Biology · Organic Chemistry
Research interest
Research interests include Cancer research, Triple-negative breast cancer, PI3K/AKT/mTOR pathway, Metastasis, Chemistry, and In vivo.
Tissue factor overexpression in triple-negative breast cancer promotes immune evasion by impeding T-cell infiltration and effector function
RORγt agonist enhances anti-PD-1 therapy by promoting monocyte-derived dendritic cells through CXCL10 in cancers
LS‐106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo
BCL9/BCL9L promotes tumorigenicity through immune-dependent and independent mechanisms in triple negative breast cancer
Sphingomyelin synthase 2 facilitates M2-like macrophage polarization and tumor progression in a mouse model of triple-negative breast cancer
A Novel mTORC1/2 Inhibitor (MTI-31) Inhibits Tumor Growth, Epithelial–Mesenchymal Transition, Metastases, and Improves Antitumor Immunity in Preclinical Models of Lung Cancer
Non-immunogenic, low-toxicity and effective glioma targeting MTI-31 liposomes
Novel-smoothened inhibitors for therapeutic targeting of naïve and drug-resistant hedgehog pathway-driven cancers
Pathological expression of tissue factor confers promising antitumor response to a novel therapeutic antibody SC1 in triple negative breast cancer and pancreatic adenocarcinoma
mTOR complex-2 stimulates acetyl-CoA and <i>de novo</i> lipogenesis through ATP citrate lyase in HER2/PIK3CA-hyperactive breast cancer